West Pharmaceutical Services, Inc. (NYSE: WST) has announced significant changes to its executive leadership team as part of its succession planning process. Bernard J. Birkett, the Senior Vice President and Chief Financial Officer, has expressed his intention to retire from his current position this year. The company has initiated a search for his successor and plans for Birkett to remain as CFO until the transition is complete, after which he will continue as an advisor to facilitate a seamless handover.
Shane Campbell has been appointed as the Senior Vice President and Chief Proprietary Segment Officer, effective May 5, 2025. Campbell joins West from Carlisle Companies Inc., where he served as the Chief Commercial Officer of the construction materials business. He brings extensive global management experience across operations, engineering, commercial, and strategy, with a career spanning over 20 years at Dupont in various senior global leadership roles.
Eric M. Green, President, Chief Executive Officer, and Chair of the Board, expressed his gratitude for Birkett's contributions over the past seven years, emphasizing his critical role in helping West navigate the challenges of the global pandemic, destocking complexities, and the emergence of GLP-1s. Birkett's transition back to focusing solely on his responsibilities as Chief Financial Officer in April 2024 was highlighted, acknowledging his pivotal contributions to strengthening West's financial and business profile.
In a separate press release, West announced its first-quarter 2025 financial results, which will be discussed in a conference call at 9:00 a.m. Eastern Time. The company has invited participants to register in advance to ask questions on the call, indicating an intention to engage with stakeholders and provide insights into its performance and business expectations.
These leadership changes and the forthcoming financial results conference call reflect West's commitment to transparent communication and strategic succession planning, signaling a proactive approach to sustaining its success and furthering its long-term growth. Today the company's shares have moved -3.5% to a price of $210.65. For more information, read the company's full 8-K submission here.
